pembrolizumab,cisplatin,gemcitabine,Durvalumab
merck,astrazeneca
['key,note,966', 'gi ', 'pembro']
second positive gi cancer ph3 trial at #aacr23 today: significant os benefit of pembro added to gem/cis vs gem/cis alone in advanced/metastatic biliary tract cancer in keynote-966. highly similar to topaz trial results - a new option for first-line btc. 
Academic GI Cancer Centre in the City of London. Delivering evidence-based treatments and clinical trials to patients. Informing and education patients and HCPs